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Abstract 
Background: Atrial flutter or fibrillation (AFF) remains a major chronic complication of the 
Fontan procedure. This complication further predisposes this patient population to 
thromboembolic events. However, the incidence of thromboembolic complications in Fontan 
patients with AFF prior to or acutely after electrical cardioversion is unknown. 
Objectives: This study aimed to characterize the risk of post-cardioversion thromboembolic 
events in this population. 
Methods: We performed a retrospective medical record review of all patients with a history of 
Fontan operation treated with direct current (DC) cardioversion for AFF at Riley Children’s 
Hospital between June 1992 and March 2014.  
Results: A total of 57 patients were identified and reviewed. A total of 216 episodes of AFF 
required electrical cardioversion. Patients were treated with anticoagulation/antiplatelet therapy 
in 86.1% (n=186) of AFF episodes. Right atrial or Fontan conduit clots were observed in 33 
patients (57.9%) with 61 episodes of AFF. Approximately half (49.2%, N=30) of these episodes 
were treated immediately with electrical cardioversion. Twenty-five of 33 (75.8%) patients with 
intracardiac thrombi had an atriopulmonary Fontan. Five (15.2%) patients with a lateral caval 
tunnel had clots in the Fontan conduit, and three (9.1%) patients with right atrium to right 
ventricular outflow tract (RVOT) connections presented with right atrial mural thrombi. Nine of 
the 57 (15.8%) patients had documented stroke, and three (5.3%) patients had pulmonary emboli 
during follow-up, although none of these emboli were associated with electrical cardioversion. 
Conclusion: The risk of thrombus and thromboembolism associated with AFF is high in the 
Fontan population. However, the risk of thromboembolism associated with cardioversion in the 
setting of anticoagulation is very low. 
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Abbreviations: 
AFF: atrial flutter or fibrillation 
aPTT: activated partial thromboplastin time 
DC: direct current 
IART: intra-atrial re-entrant tachycardia  
INR: international normalized ratio transthoracic echocardiograms  
RA: right atrium 
RVOT: right ventricular outflow tract 
TEE: trans-esophageal echocardiogram 
TTE: trans-thoracic echocardiogram 
 tPA: tissue plasminogen activator  
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Introduction
Patients with single-ventricle Fontan palliation are highly susceptible to thrombus 
formation according to Virchow’s triad of thrombogenesis, which includes abnormally low 
venous blood flow, hypercoagulability, and the use of intracardiac prosthetic materials with 
vessel wall abnormalities and endothelial injury (1). The prevalence of thrombosis after Fontan 
palliation is reportedly 1–33%, with a high, immediate risk of thrombosis after surgery and an 
increased risk for Fontan patients surviving into adulthood (2-11). The anticoagulation regimens 
for these patients vary (3, 11). 
Atrial flutter or fibrillation (AFF) remains a significant complication in the expanding 
population of Fontan palliation survivors, with an incidence of 16-17% 5 years after Fontan 
surgery and an incidence of 50% by 12 years (12-14). Despite the various modifications of the 
Fontan surgery, including lateral caval tunnel and extracardiac conduits, as well as revisions and 
primary maze interventions, tachyarrhythmia persists (15). The treatment of AFF in this 
population is difficult. If not controlled, AFF can lead to rapid atrio-ventricular conduction, 
hemodynamic deterioration and sudden death (13). Given this increased morbidity and mortality, 
acute treatment focuses on medical and electrical cardioversion (16, 17). The increased risk of 
intra-atrial and Fontan thrombus formation in patients with AFF further complicates treatment 
(18). 
AFF in the adult patient with an anatomically normal heart increases the risk of intra-
atrial thrombus and stroke (19). The risk of thromboembolic events increases with cardioversion 
(16). These events are caused by either mobilization of the existing thrombus or “atrial stunning” 
(20). These risks have defined the standard of care, which includes systemic anticoagulation for 
this patient population and thrombus resolution prior to cardioversion (3). Systemic 
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anticoagulation prior to cardioversion has also become the standard of care for Fontan patients 
with AFF and documented thrombus (3). 
This study sought to assess the risk of acute thromboembolism in Fontan patients with 
AFF who were treated with electrical cardioversion. 
 
Methods 
This study was approved by the institutional review board of the Indiana University 
School of Medicine. 
A retrospective review of medical records was completed for all 57 eligible Fontan 
surgery patients with AFF who underwent electrical cardioversion between June 1992 and March 
2014 at Riley Children’s Hospital in Indianapolis, Indiana. During this study period, 340 Fontan 
procedures were performed at Riley Children’s Hospital.  AFF included both intra-atrial re-
entrant tachycardia (IART, complex atrial flutter) and atrial fibrillation. The diagnosis was 
confirmed by 12-lead electrocardiography, which was interpreted by the treating cardiologists as 
documented in the medical record. The medical record did not always distinguish the diagnostic 
rhythm as regular or irregular to segregate the analyses. Patients were identified using a 
cardiology database of electrically cardioverted patients and cross-referenced with the surgery 
database. Patients without Fontan palliation who underwent electrical cardioversion were 
excluded. 
 Echocardiography was performed prior to cardioversion in all patients and was 
interpreted by experienced echo-cardiographers. Echocardiographic evaluations were performed 
by an independent observer (J.L) who examined the digitized images (Syngo, Siemens) after the 
original examinations. These digitized images were available after January 2000. When 
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transthoracic study images were sub-optimal or patients underwent electrical cardioversion with 
other surgical procedures, such as Fontan conversion or pacemaker generator changes, a 
transesophageal study was performed prior to the procedure. A thrombus was defined as an 
echo-reflective mass with a different texture than the underlying endocardium and evident in at 
least two different orthogonal planes. The thickening of the internal surface of the Fontan 
pathway and spontaneous contrast were not considered an intracardiac thrombus. Rarely, 
angiography was employed for hemodynamic evaluation, and chest computer tomography, 
cardiac magnetic resonance imaging or lung perfusion scan studies were completed but were 
never the sole means by which a thrombus was diagnosed. Organized thrombi were defined as 
well-circumscribed, older and non-mobile thrombi with a broad-based/secure attachment to the 
heart wall with occasional focal calcification (increased echo-brightness). Non-organized 
thrombi were defined as new thrombi with a sessile or pedunculated base that were mobile and 
protruding during the cardiac cycle and disappeared rapidly after anti-thrombolytic therapy. 
The use of thromboprophylaxis regimens for individual Fontan patients has been at the 
primary cardiologist’s discretion. However, our institutional approach since 2005 has been to 
prescribe aspirin (5 mg/kg/day) at a maximal dose of 81 mg after the Fontan operation for 
primary thromboprophylaxis indefinitely in conjunction with warfarin or enoxaparin 
immediately after Fontan procedures with fenestration (after removal of an intra-atrial line). 
Enoxaparin is administered as a bridge during the initiation of warfarin. For patients on warfarin 
therapy, the dose was adjusted to maintain the prothrombin time and international normalized 
ratio (INR) between 1.8 and 2.2. The duration of this early, post-Fontan anticoagulation was at 
the discretion of the primary cardiologists, but most cardiologists at our institution prefer 
continuous anticoagulation therapy if fenestration is evident. An INR less than 1.5 was classified 
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as non-compliance with warfarin administration. For patients exhibiting a mobile non-organized 
intra-cardiac thrombus, heparin was initially administered at a dose of 20 units/kg/hour and 
titrated to the goal activated partial thromboplastin time (aPTT) of 53 to 84 seconds. For patients 
on chronic warfarin therapy, the dose for the acute treatment of intracardiac thrombi was 
adjusted to achieve a prothrombin time and INR between 2.5 and 3.5 for at least 2 weeks. Anti-
thrombolytic therapy with tissue plasminogen activator (tPA) was used at the discretion of the 
treating cardiologists and intensivist. 
Electrical cardioversion was performed 1) when there was no evidence of intracardiac 
thrombi; 2) when thrombi were organized; 3) after adequate anticoagulation therapy and the 
resolution of fresh thrombi by echocardiography, or 4) after a rapid ventricular response with 
hemodynamic compromise. Acutely successful cardioversion was defined as a sustained AFF-
free rhythm until patient discharge from the recovery area. Patients with no evidence of AFF for 
at least 2 years after their last documented AFF were considered “AFF-free.” 
A thromboembolic event was defined as patients with evidence (by history, examination 
and imaging studies) of either central nervous system infarction (stroke) (21) or pulmonary 
emboli resulting in the obstruction of the pulmonary artery by thrombus. These events were 
confirmed by computerized tomography, magnetic resonance imaging, or autopsy. 
Statistical Analysis 
Descriptive statistics including the mean, median, and interquartile ranges for continuous 
variables and counts and percentages for categorical variables were calculated. Chi-square 
analysis was performed to compare mortality between patients with and without intra-cardiac 
thrombi. 
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Results 
Study population 
 Fifty-seven patients (68.4% male) who underwent Fontan procedures during the study 
period were reviewed with a median (25th, 75th percentile) follow-up of 8.1 years (3.25, 12.9) 
from the first documented episode of AFF to last follow-up. The median age (25th, 75th 
percentile) at Fontan surgery was 5.4 (3.1, 6.8) years. The median ages of the patients who 
underwent the classic Fontan procedure, lateral tunnel Fontan procedure, extracardiac Fontan 
procedure and RA to RVOT were 7.0, 3.4, 2.9 and 6.2 years, respectively. Table 1 summarizes 
the patients’ initial diagnoses. Table 2 summarizes the types of Fontan surgeries. 
The median (25th, 75th percentile) age of the first episode of atrial flutter was 9.4 (6.9, 
12.9) years after the Fontan procedure. The median (25th, 75th percentile) age of the patients 
who underwent electrical cardioversion was 17.3 (11.1, 20.8) years, a median (25th, 75th 
percentile) of 10.5 (7.2, 14.6) years after the Fontan procedure. A total of 57 patients underwent 
216 electrical cardioversion procedures (1 procedure in 19 patients, 2 procedures in 8 patients; 3 
procedures in 9 patients; 4 procedures in 5 patients, 5 procedures in 2 patients, 6 procedures in 5 
patients, 7 procedures in 4 patients, 8 procedures in 1 patient, 9 procedures in 2 patients, 10 
procedures in 1 patient, and 30 procedures in 1 patient). Electrical cardioversion was successful 
in 208 (96.3%) of the 216 procedures. A significant majority of procedures were elective (n=208, 
96.3%). Of the eight emergent cardioversions due to a rapid ventricular response, six procedures 
converted to a normal sinus rhythm. Two procedures in emergent situations did not successfully 
convert to a normal rhythm and represented terminal events before demise. 
 
Echocardiogram 
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A total of 202 transthoracic echocardiograms (TTEs) and 28 trans-esophageal 
echocardiograms (TEEs) were performed prior to cardioversion. Intracardiac thrombi (Figure 1) 
were detected in 85 TTEs and 12 TEEs in 31 patients. Intracardiac thrombi that were not 
observed prior to cardioversion were identified in two patients 6 years and 7 years after 
cardioversion on additional imaging follow-up, both of them had AFF at that time without 
receiving electrical cardioversion secondary to refractory to direct current cardioversion in the 
past.  Right atrial thrombi or Fontan conduit thrombi were observed in 33 patients (57.9%). 
Forty-two patients (73.7%) presented with decreased systemic ventricular function. Eight 
(14.0%) patients had at least moderate to severe systemic atrioventricular valve regurgitation, all 
in association with decreased systolic systemic ventricular function. 
 
Anticoagulation 
Of the 216 episodes of atrial flutter experienced by the 57 subjects, 64 (29.6%) electrical 
cardioversions occurred in patients who had been taking only warfarin/heparin, 72 (33.3%) 
procedures were performed on patients taking both aspirin and warfarin/heparin, 50 (23.2%) 
procedures were performed on patients who had been taking only aspirin, and 30 (13.9%) 
procedures were performed on patients who were not taking any anticoagulation prophylaxis, 
mostly due to non-compliance. 
 
Intracardiac thrombus 
 Of the 33 patients with intracardiac clots, 11 (33.3%) had intracardiac thrombi at the time 
of atrial flutter diagnosis, and 22 (66.7%) had documented intracardiac clots at a later point in 
time after the initial episode of atrial flutter. The anatomical location and outcomes of 
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intracardiac thrombi are summarized in Table 3. Most intracardiac thrombi were observed in the 
systemic venous circulation, and one patient who had undergone a classic Fontan procedure 
exhibited a mural thrombus in the dilated right atrium and another thrombus in the left atrial 
appendage. One patient presenting with a dilated coronary sinus and dilated right atrium after the 
classic Fontan operation had recurrent coronary sinus thrombus after extracardiac Fontan 
conversion. He died of a massive stroke 10 months later. Three patients had a history of 
pulmonary emboli prior to cardioversion. 
Of the sixty-one episodes of atrial flutter in patients associated with intracardiac thrombi, 
38 (62.3%) were organized mural thrombi, whereas 23 (37.7%) were new, mobile, non-
organized thrombi. A comparison of the symptoms with intracardiac thrombi and non-
intracardiac thrombi groups is summarized in Table 4. The group with intracardiac thrombi had a 
higher prevalence of pre-syncope and heart failure. The management of AFF with intracardiac 
thrombi is summarized in Figure 2. The majority of patients in the organized thrombi group 
received electrical cardioversion without delay in the setting of adequate anticoagulation. The 
patients who did not undergo electrical cardioversion were pharmacologically rate-controlled 
(Figure 2). Overall, only one patient with intracardiac thrombi received emergent electrical 
cardioversion without adequate anticoagulation; the other patient, who presented with syncope 
and atrial flutter with intracardiac thrombi, had received adequate anticoagulation therapy. 
Resolution of intracardiac thrombi was observed in twenty-six patients (78.8%) by either 
transthoracic or transesophageal echocardiogram. In nineteen patients (57.6%), the thrombus 
resolved upon treatment with heparin, warfarin or their combination. In one patient with a 
systemic venous atrium thrombus and pulmonary emboli, the thrombi resolved upon systemic 
administration of tissue plasminogen activator (tPA). Local tPA injection resolved thrombi in the 
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right atrium and pulmonary arteries of another patient. Five patients underwent surgical 
thrombectomies during Fontan conversion, and one patient received a heart transplant. One 
patient experienced recurrent right atrial thrombi 3 years following classic to extracardiac Fontan 
conversion. 
  
Long-term follow-up 
Thirty-two patients (56.1%) continued to suffer from recurrent atrial flutter. Twenty-five 
patients (43.9%) remained in normal sinus or paced rhythm. The long-term follow-up of this 
specific cohort revealed mortality in 14 patients (24.6%); none of these deaths occurred during or 
as a result of cardioversion. The mortality rate was 27.3% (n=9) in patients with intracardiac 
thrombi, the mortality rate was 20.8% (n=5) in patients without intracardiac thrombi (P-value 
=0.4624). 
 
Thromboembolic Events 
 A total of 13 thromboembolic events occurred in 12 of the 57 study patients, 
corresponding to an overall incidence of 21.1%. Nine patients experienced systemic cerebral 
events. One patient had a stroke prior to completion of the Fontan procedure, and 3 patients 
experienced cerebral embolic events prior to the first documented episode of AFF. Two patients 
had thrombi in either the extracardiac conduit or the coronary sinus during the cerebral 
thromboembolic events. None of these patients underwent fenestration in their Fontan procedure. 
The majority of patients who experienced thromboembolic events were taking anticoagulants at 
the time of the event. Three patients had pulmonary emboli with evidence of a dilated right 
atrium and right atrium thrombus. These three patients had all undergone the classic 
13 
 
atriopulmonary Fontan operation. Two deaths occurred secondary to pulmonary emboli. Table 5 
summarizes the patients with thromboembolic events. None of these events were associated with 
electrical cardioversion. 
 
 
Discussion 
The following conclusions were made based on this study of patients with Fontan 
palliation and AFF treated with electrical cardioversion, 1. Fontan patients in our institution 
undergoing electrical cardioversion for AFF do not experience acute post-conversion 
thromboembolic events. 2. Intracardiac thrombi is much more common in Fontan patients with 
AFF in our study (57.8%) compared with the reported prevalence of 1%-33% (2-11).  
Fontan patients with AFF may be at higher risk of thromboembolism than Fontan patients 
without AFF due to a loss of atrial-ventricular synchrony, decreased systemic ventricular 
function (73.7% in our study), stasis in the systemic venous pathway, increased platelet 
activation through inflammation secondary to hypoxia (22), and, as suggested by accumulating 
evidence, a rapid atrial rate and rhythm associated with a pro-thrombotic state (23). Rates of 
systemic venous and arterial thromboembolic complications as high as 33% in Fontan patients 
have been reported, but the incidence of atrial flutter is unknown (2-11). Although more than 
half of our study patients had intracardiac thrombi, the incidence of stroke in our study patients 
(15.8%, n=9) was not higher than the published rates, which may be explained by the 
observation that the intracardiac thrombi identified in this study were mostly located in the 
systemic venous system. 
The cohort in this study included a large number of patients who had undergone a classic 
Fontan procedure (61.4%, n=35). The interposition of a passive chamber between the systemic 
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veins and pulmonary arteries is likely responsible for the flow inefficiency and increased energy 
requirements observed for a dilated right atrium (24). Because of the high incidence of dilated 
right atrium complications such as atrial arrhythmia and atrial thrombus formation in the 
atriopulmonary Fontan circulation, the Fontan procedure has been modified to include a total 
cavopulmonary artery connection (25) and extracardiac cavopulmonary artery connection. 
Surgeons at our institution stopped performing the atriopulmonary Fontan connection in 1995, 
and the majority of patients thereafter underwent Fontan procedures utilizing an intracardiac 
tunnel with or without fenestration. 
Despite aggressive surgical and medical treatment, atrial flutter is difficult to treat in 
Fontan patients, and only 43.9% (n=25) of our study patients remained free of atrial flutter. 
Atrial flutter is associated with a negative hemodynamic impact. Atrial flutter is poorly tolerated 
in Fontan patients; we observed decreased cardiac function in 73.7% of these patients. Since 
1962, electrical cardioversion in the general population has enabled lower doses of maintenance 
antiarrhythmic medications and restoration of the rhythm to normal in more than 90% of patients 
(17). However, the association of stroke with cardioversion has been recognized for more than 
60 years (26,27). Post-cardioversion thromboembolic events can occur with a pharmacological 
strategy, electrical cardioversion or even spontaneous cardioversion. Although the incidence of 
these embolic events is less than 1% within 30 days, the risk of thromboembolic complications 
reaches approximately 10% in the presence of multiple risks (19). In our study, under routine 
surveillance of intracardiac thrombi and anticoagulation administration, none of the 
thromboembolic events were related to elective electrical cardioversion. Because 73.7% of AFF 
episodes in Fontan patients associated with decreased cardiac function and the majority of 
intracardiac thrombi occur in the venous/Fontan pathway, the restoration of normal sinus rhythm 
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by electrical cardioversion should not be delayed. At our institution, we routinely use 
transthoracic echocardiograms to survey the intracardiac thrombi prior to electrical 
cardioversion. Consequently, cardioversion is not delayed in case of adequate anticoagulation 
therapy and without evidence of new, mobile and pedunculated intracardiac thrombi. A 
transesophageal echocardiogram was performed when the transthoracic echocardiogram images 
were suboptimal or when patients were sedated. For patients with intracardiac thrombi without 
adequate anticoagulation, heparin/warfarin was administered to achieve INR values ranging from 
2.5-3.5 for at least 2 weeks. Electrical cardioversion was performed without delay if patients 
presented with hemodynamic compromise, irrespective of adequate anticoagulation. 
As surgical techniques have improved and the number of Fontan patients has increased, 
our experience in the management of complications associated with Fontan palliation has also 
increased. Our study demonstrates that elective electrical cardioversion is not associated with an 
increased risk of thrombotic stroke or pulmonary emboli in this high-risk Fontan population. 
Thus, electrical cardioversion is safe for patients with Fontan circulation on anticoagulation 
therapy. 
Study limitations 
Patients in our study did not undergo surveillance or routine central neural system 
imaging, and clinically silent events may have been missed. In patients with pacemaker 
placement, we were unable to obtain magnetic resonance images or magnetic resonance 
angiograms, and a small thromboembolic embolus may have been missed. Not all patients had 
TEEs; therefore, some small thrombi might not have been identified, particularly for patients 
with a poor imaging window. We recognized the possibility of missing intracardiac thrombi on a 
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transthoracic echocardiogram, but none of the electrical cardioversions in our study were 
associated with stroke or pulmonary emboli. A retrospective study does not permit 
characterization of the study cohort as precisely and accurately as a well-executed prospective 
study. We depended on the data recorded by the physicians who performed electrical 
cardioversion and were responsible for the follow-up. However, because of the good coverage of 
electronic patient records and stability of the population, we were able to reliably review 
outcomes for all included patients at subsequent outpatient and hospital visits. 
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Perspectives:  
Core Clinical Competencies and Implications 
The Fontan population is at high risk for thromboembolic complications. As AFF remains a major 
chronic complication of the Fontan procedure, identifying the risk of this complication is critical for 
proper patient management to improve outcomes. Our findings indicate that performing cardioversion is 
safe in Fontan patients under anticoagulation. 
Translational Outlook 
Further studies are needed to define the anticoagulation regimen in the growing population with 
contemporary modification of the Fontan operation with a less frequent IART and AFF. 
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Figure legends 
Figure 1. Intracardiac thrombi: A) A 4.3X3.12 cm right atrium (RA) mural thrombus (arrow) in a 
dilated RA imaged by TTE; B) a thrombus in the lateral caval tunnel conduit (arrow); C) a 
thrombus in a dilated coronary sinus (CS) (arrow); D) two thrombi (arrows) in the right atrium 
(RA) to pulmonary artery (PA) junction; E) TEE of a patient with an extracardiac conduit, 
revealing a thrombus in the posterior wall of the conduit (arrow); F) TEE of a patient who had 
undergone a classic Fontan revealing a swirling flow in the dilated right atrium (RA). 
Figure 2. Flow chart of treatment for patients presenting with AFF associated with intracardiac 
thrombi. DC: direct current. 
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Table 1. Patient’s demography; N (%) 
Male 39 (68.4%)
LV dominant 40 (70.2%)    
     Tricuspid atresia    20 (35.1%)  
     Double inlet of left ventricle  10 (17.5%)
     Pulmonary atresia   7 (12.3%)
     Criss-Cross with hypoplastic RV    2 (03.5%)
     Unbalanced AV canal/hypoplastic RV 1 (01.8%)
RV Dominant 17 (29.8%) 
     Hypoplastic left heart syndrome 9 (15.7%)
     DORV with mitral stenosis/mitral atresia     4 (07.0%)
     Unbalanced AV canal/hypoplastic LV                                          2 (03.5%)
     Criss-Cross with hypoplastic LV   1 (01.8%)
     Corrected TGA with hypoplastic LV, severe PS 1 (01.8%)
 
AV: atrioventricular, DORV: double outlet of right ventricle, LV: left ventricle, PS: pulmonary 
stenosis, RV: right ventricle, TGA: transposition of great arteries 
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Table 2.  Type of Fontan operation; N (%) 
 
Type of Fontan operation Surgical interventions noted in follow-up  
Atriopulmonary connection 
35/57 (61.4%) 
Convert to extracardiac conduit with MAZE 16/35 (45.7%) 
Convert to extracardiac conduit 01/35 (02.9%) 
Convert to lateral caval Fontan 02/35 (05.7%) 
Heart  transplant 02/35 (05.7%) 
Lateral caval tunnel 
17/57 (29.8%) 
Convert to extracardiac conduit with MAZE 01/17 (05.9%)     
Right atrium to RVOT 
connection 
03/57 (05.3%) 
Convert to two ventricle repair with MAZE 01/03 (33.3%)     
Convert to extracardiac conduit with MAZE 02/03 (66.7%)     
Extracardiac conduit 
02/57 (03.5%) 
 
No conversions  
 
RVOT: right ventricular outflow tract 
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Table 3 Location and clinical outcome of inatracardiac thrombus 
Fontan connection Classic Lateral caval tunnel RA to RVOT 
Intracardiac thrombus 25/35 (71.4%) 5/17 (29.4%) 3/3 (100%) 
Location of the intracardiac 
thrombi 
   RA 17 0 3 
   RA/IVC 3 0 0 
   RA/SVC 2 1 0 
   RA/PA 1 0 0 
   RA and LAA 1 0 0 
   CS 1 0 0 
  Fontan conduit 0 3 0 
      Conduit/IVC 0 1 0 
Resolution  of intracardiac 
thrombi 
20/25 (80.0%) 4/5 (80%) 2/3 (66.7%) 
   Coumadin 7 3 2 
   Heparin + Coumadin 6 1 0 
   tPA 1 0 0 
  Surgical thrombectomy        
  /heart transplantation 
6 0 0 
Recurrence of RA thrombus 
after Fontan Conversion      
1 0 1 
CS: coronary sinus, LAA: left atrial appendage; IVC: inferior vena cava; PA: pulmonary artery, RA: right atrium, 
SVC: superior vena cava, tPA: tissue plasminogen activator 
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Table 4. Symptoms associated with atrial flutter/fibrillation 
Symptoms Group of Intracardiac 
thrombi 
(N=61) N (%) 
Group of no 
intracardiac thrombi  
(N=155) N (%) 
P value 
Asymptomatic 08 (13.11%) 20 (12.9%) P = 0.967 
Palpitation 39 (63.93%) 117 (75.48%) P = 0.089 
Chest pain 18(29.51%) 31 (20.00%) P = 0.134 
Syncope/Collapse 02 (03.28%) 02 (01.29%) P = 0.331 
Dizziness/pre-syncope 12 (19.67%) 10 (06.45%)   P = 0.004* 
Edema/Ascites 10 (16.39%) 12 (07.74%) P = 0.087 
Fatigue 18 (29.51%) 31 (20.00%) P = 0.134 
Dyspnea 20 (32.79%) 33 (21.29%) P = 0.078 
GI symptoms 14 (22.95%) 28 (18.06%) P = 0.416 
Hypoxia 08(13.11%) 17 (11.0%) P = 0.656 
Heart failure 53 (86.89%) 91 (58.71%)   P < 0.001* 
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Table 5. Data of Patients with symptomatic thromboembolic events 
Systemic thromboembolic event Venous 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10 Patient 11 Patient 12 
Anatomy Unbalance
d AV canal 
with 
HLHS 
TA TA with 
TGA 
TA Unbalance
d AV canal 
defect with 
HRV 
DILV DILV HLHS HLHS TA TA DILV 
Type of surgery Classic 
/TCPC 
RA to 
RVOT / 
TCPC 
Classic Classic Classic Classic Lateral 
caval 
tunnel 
Lateral 
caval 
tunnel 
Lateral 
caval 
tunnel 
Classic Classic Classic 
Thromboembolic  
event 
stroke Massive 
stroke 
stroke stroke stroke stroke stroke Multiple 
micro-
embolic 
stroke 
stroke Pulmonary 
embolism 
Pulmonary 
embolism 
Pulmonary 
embolism 
Relationship 
between the event 
and electrical  
cardioversion 
34 days 
after a 
spontaneou
s convert 
atrial 
flutter 
13.5 
years 
after last 
cardio-
version 
13 years 
prior to 
first 
episode of 
atrial 
flutter 
After 
ablation 
10.7 ears 
prior to his 
first 
episode of 
atrial 
flutter 
After 
diagnostic 
cath 
After 
Fontan 
operation , 
7 years 
prior to 
first 
episode of 
atrial 
flutter 
12 months 
after 
cardio-
version 
2 days 
prior to 
cardio-
version 
5 days 
prior to 
cardio-
version 
1 day prior 
to  
emergent 
cardio-
version 
14 years 
after last 
cardio-
version 
Intracardiac 
thrombi 
Extra-
cardiac 
conduit 
Coronar
y sinus 
No No No No No No No Right 
atrium 
Right 
atrium 
Right 
atrium 
Age at event 16.4y/o 39.3y/o 6y/o 13.6y/o 6.3y/o 18m/o 12 y/o 10.1y/o 9.7y/o 20.1y/o 34.6y/o 30 y/o 
Anticoagulant warfarin 
aspirin 
No 
(non-
complia
nt) 
aspirin warfarin  
aspirin 
aspirin warfarin No aspirin aspirin tPA Heparin tPA 
Outcome mild fine 
motor 
deficient, 
almost 
complete 
resolution 
of left 
hemi-
paresis 
Died 
from 
massive 
embolic 
stroke 
Residual 
left 
hemiparesi
s 
Died of 
massive 
cerebellar 
embolic 
stroke 11 
months 
later 
Residual 
left 
hemiparesi
s 
Resolution 
of left 
hemiparesi
s 
Resolution 
of left 
hemi-
paresis 
Improved 
memory, 
attends 
regular 
classes 
Resolution 
of 
hemiparesi
s but died 
of plastic 
bronchitis 
and heart 
failure 6 
years later 
Resolution 
of 
thrombus 
Died of 
heart 
failure and 
pulmonary 
emboli 
Resolution 
of 
pulmonary 
emboli but 
died of 
MOF 
